Accueil>>Peptides>>[Des-Arg9]-Bradykinin

[Des-Arg9]-Bradykinin (Synonyms: (Des-Arg9)-BK, (Des-Arg9)-Kallidin, (Des-Arg9)-KD, RPPGFSPF-OH)

Catalog No.GC35015

La [Des-Arg9]-bradykinine est un agoniste des récepteurs de la bradykinine (B1) qui affiche une sélectivité pour les récepteurs B1 par rapport aux récepteurs B2.

Products are for research use only. Not for human use. We do not sell to patients.

[Des-Arg9]-Bradykinin Chemical Structure

Cas No.: 15958-92-6

Taille Prix Stock Qté
5mg
52,00 $US
En stock
10mg
81,00 $US
En stock
25mg
176,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

[Des-Arg9]-Bradykinin is a Bradykinin (B1) receptor agonist that displays selectivity for B1 over B2 receptors.

The B2 receptor mediates the action of bradykinin (BK) and lysyl-bradykinin (Lys-BK), the first set of bioactive kinins formed in response to injury from kininogen precursors through the actions of plasma and tissue kallikreins, whereas the B1 receptor mediates the action of [Des-Arg9]-Bradykinin (des-Arg9-BK) and Lys-des-Arg Arg9-BK, the second set of bioactive kinins formed through the actions of carboxypeptidases on BK and Lys-BK, respectively[1].

References:
[1]. Leeb-Lundberg LM, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005 Mar;57(1):27-77.

Avis

Review for [Des-Arg9]-Bradykinin

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for [Des-Arg9]-Bradykinin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.